COMPASS Pathways plc (NASDAQ:CMPS) Given Consensus Rating of “Buy” by Analysts

COMPASS Pathways plc (NASDAQ:CMPS) has earned an average rating of “Buy” from the six research firms that are presently covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have issued a report on the stock in the last year is $30.60.

Several research analysts have recently commented on the company. HC Wainwright cut their price objective on COMPASS Pathways from $60.00 to $45.00 and set a “buy” rating for the company in a report on Thursday. Maxim Group decreased their price target on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $18.00 price objective on shares of COMPASS Pathways in a report on Wednesday, January 15th.

COMPASS Pathways Price Performance

NASDAQ:CMPS opened at $4.57 on Friday. The firm has a market capitalization of $312.68 million, a price-to-earnings ratio of -2.08 and a beta of 2.28. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. The stock has a fifty day moving average of $4.10 and a 200 day moving average of $5.49. COMPASS Pathways has a 52-week low of $3.16 and a 52-week high of $12.75.

Hedge Funds Weigh In On COMPASS Pathways

Several institutional investors and hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. bought a new stake in COMPASS Pathways in the fourth quarter worth $41,000. Flagship Harbor Advisors LLC bought a new stake in shares of COMPASS Pathways in the 4th quarter valued at about $43,000. Wealthfront Advisers LLC bought a new stake in shares of COMPASS Pathways in the 4th quarter valued at about $43,000. Conservest Capital Advisors Inc. boosted its holdings in COMPASS Pathways by 28.9% during the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock valued at $51,000 after acquiring an additional 3,000 shares during the period. Finally, Simplify Asset Management Inc. bought a new position in COMPASS Pathways during the 4th quarter worth approximately $54,000. Institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.